Patient Convenience and Formulation Innovations

This segment explores innovations in therapy administration designed to improve patient convenience and overall treatment experience. Panelists discuss the development of subcutaneous formulations of amivantamab, emphasizing the significant advantages for patients compared to traditional intravenous administration. Subcutaneous administration reduces clinic time, lowers the risk of infusion-related reactions, and simplifies scheduling, making long-term therapy more feasible for patients and improving adherence. The panel references data from the PALOMA trials, showing strong patient preference for subcutaneous formulations and suggesting potential improvements in efficacy and tolerability. The discussion highlights logistical and clinical benefits, noting that reduced infusion times and simplified administration protocols decrease the burden on healthcare teams while enhancing the patient experience. Experts emphasize that such innovations are especially important for patients on long-term therapy, for whom repeated intravenous administration can become cumbersome and disruptive. Beyond convenience, subcutaneous administration may facilitate more consistent dosing and reduce the likelihood of therapy interruptions. The panel predicts rapid adoption of these formulations, suggesting that intravenous therapy will largely become obsolete in the context of widespread subcutaneous use. Overall, this segment underscores how formulation advances complement efficacy improvements, demonstrating the ongoing evolution of patient-centered cancer care.